Summary:
- Breyanzi, a new cancer treatment, has been approved by the U.S. FDA for adults with a type of blood cancer called marginal zone lymphoma.
- Breyanzi is a type of CAR-T cell therapy, which uses the patient's own immune cells to fight the cancer.
- This approval is significant because Breyanzi is the first and only CAR-T cell therapy approved for this type of lymphoma.